In addition, high expression of c-Met has been observed in more than 80% of patients with HCC where it is correlated with poor progression-free survival and where it may be a predictor for sensitivity to agents such as the tyrosine kinase inhibitor sorafenib [8]. This evidence concerns the gene MET and hepatocellular carcinoma.